Adjunctive Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Type 1 Diabetes Mellitus

Pharmacotherapy

Volumn 36, Issue 9, 2016, Pages 1011-1020

  Harris, Kira B ^a   Boland, Cassie L ^a  

^a WINGATE UNIVERSITY   (United States)

Author keywords

exenatide; glucagon like peptide 1 receptor agonists; liraglutide; type 1 diabetes mellitus

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; LIRAGLUTIDE; PLACEBO;

BODY WEIGHT; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INJECTION SITE NODULE; INSULIN DEPENDENT DIABETES MELLITUS; NAUSEA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VOMITING; WEIGHT REDUCTION;

EID: 84990205615     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1804     Document Type: Review

References (42)

1. Kielgast U, Holst JJ, Madsbad S. Treatment of type 1 diabetic patients with glucagon-like peptide 1 (GLP-1) and GLP-1R agonists. Curr Diabetes Rev 2009;5:266–75.
2. Pettus J, Hirsch I, Edelman S. GLP-1 agonists in type 1 diabetes. Clin Immunol 2013;149:317–23.
3. Standards of medical care in diabetes—2016. Diabetes Care 2016;39:S1–108.
4. George P, McCrimmon RJ. Potential role of non-insulin adjunct therapy in type 1 diabetes. Diabet Med 2012;30:179–88.
5. Frandsen CS, Dejgaard TF, Madsbad S. Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus. Lancet Diabetes Endocrinol. Published Online March 8, 2016. DOI:10.1016/S213-8587(16)00039-5.
6. Ellis SL, Moser EG, Snell-Bergeon JK, Rodionova AS, Hazenfield RM, Garg SK. Effect of sitagliptin on glucose control in adult patients with type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med 2011;28:1176–81.
7. Garg SK, Moser EG, Bode BW, et al. Effect of sitagliptin on postprandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocr Pract 2013;19:19–28.
8. Giampietro O, Giampietro C, Bartola LD, Masoni MC, Matteucci E. Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and 2 diabetes. Drug Des Devel Ther 2013;7:99–104.
9. Griffin KJ, Thompson PA, Gottschalk M, Kyllo JH, Rabinovitch A. Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicenter, randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 2014;1:710–8.
10. Lind M, Jendle J, Torffvit O, Lager I. Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Prim Care Diabetes 2012;6:41–6.
11. Kielgast U, Holst J, Madsbad S. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function. Diabetes 2011;60:1599–607.
12. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372:1240–50.
13. Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly result in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011;96:1301–10.
14. Sheffield CA, Kane MP, Busch RS. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection. Pharmacotherapy 2007;27:1449–55.
15. Hari Kumar KVS, Shaikh A, Prusty P. Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study. Diabetes Res Clin Pract 2013;100:e55–8.
16. Rother KI, Spain LM, Wesley RA, et al. Effects of exenatide alone and in combination with daclizumab on β-cell function in long-standing type 1 diabetes. Diabetes Care 2009;32:2251–7.
17. Sarkar G, Alattar M, Brown RJ, Quon MJ, Harlan DM, Rother KI. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes Care 2014;37:666–70.
18. Raman VS, Mason KJ, Rodriquez LM, et al. The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care 2010;33:1294–6.
19. Traina AN, Lull ME, Hui AC, Zahorian TM, Lyons-Patterson J. Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy. Can J Diabetes 2014;38:269–72.
20. Buse JB, Rosenstock J, Schmidt WE, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39–47.
21. Buse JB, Fauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomized, open-label study. Lancet 2013;381:117–24.
22. Harrison LB, Mora PF, Clark GO, Lingvay I. Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs. J Investig Med 2013;61:40–4.
23. Varanasi A, Bellini N, Rawal D, et al. Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol 2011;165:77–84.
24. Kielgast U, Krarup T, Holst J, Madsbad S. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual β-cell function. Diabetes Care 2011;34:1463–8.
25. Frandsen CS, Dejgaard TF, Holst JJ, Andersen HU, Thorsteinsson B, Madsbad S. Twelve-week treatment with liraglutide as add-on to insulin in normal-weight patients with poorly controlled type 1 diabetes: a randomized, placebo-controlled, double-blind parallel study. Diabetes Care 2015;38:2250–7.
26. Kuhadiya N, Dhindsa S, Ghanim H, et al. Addition of liraglutide to insulin in patients with type 1 diabetes: a randomized placebo-controlled clinical trial of 12 weeks. Diabetes Care 2016;39:1027–35.
27. Kuhadiya ND, Malik R, Bellini NJ, et al. Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus. Endocr Pract 2013;19:963–7.
28. Dejgaard TF, Frandsen CS, Hansen TS, et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2016;4:221–32.
29. Command Hospital. Comparison between GLP-1 analogues and DPP-4 inhibitors in type 1 diabetes mellitus. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; 2000. Available from https://clinicaltrials.gov/ct2/show/NCT01235819; NLM identifier: NCT01235819.
30. Albert Einstein College of Medicine Yeshiva University. Exenatide (Byetta) vs. pramlintide (Symlin): role in post-prandial hyperglycemia. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine. 2000. Available from https://clinicaltrials.gov/ct2/show/NCT01269047; NLM identifier: NCT01269047. Accessed March 15, 2016.
31. Novo Nordisk. A 26-week randomised, insulin capped, placebo-controlled, double-blind, parallel group, multinational, multi-centre trial. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; 2000. Available from https://clinicaltrials.gov/ct2/show/NCT02098395; NLM identifier: NCT02098395. Accessed March 15, 2016.
32. Centre Hospitalier Universitaire de Quebec; CHU de Quebec. Cross-over, double-blind, unicentric, 52 week trial of liraglutide in type 1 diabetes. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; 2000. Available from https://clinicaltrials.gov/ct2/show/NCT01787916; NLM identifier: NCT01787916. Accessed March 15, 2016.
33. University at Buffalo. Liraglutide in overweight patients with type 1 diabetes. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; 2000. Available from https://clinicaltrials.gov/ct2/show/NCT01753362; NLM identifier: NCT01753362. Accessed March 15, 2016.
34. Kaleida Health. Liraglutide in the treatment of type 1 diabetes mellitus. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; 2000. Available from https://clinicaltrials.gov/ct2/show/NCT01722266; NLM identifier: NCT01722266. Accessed March 15, 2016.
35. University at Buffalo. Liraglutide in type 1 diabetes. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; 2000. Available from https://clinicaltrials.gov/ct2/show/NCT01722240; NLM identifier: NCT01722240. Accessed March 15, 2016.
36. Novo Nordisk. The efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes. A 52-week randomised, treat-to-target, placebo-controlled, double blinded, parallel group, multinational, multi-centre trial. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; 2000. Available from https://clinicaltrials.gov/ct2/show/NCT01836523; NLM identifier: NCT01836523. Accessed March 15, 2016.
37. Hvidovre University Hospital. Treatment with liraglutide as add-on to insulin in type 1 diabetic patients. Effects on glycemic control and counter regulation and cognitive performance during hypoglycaemia. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; 2000. Available from https://clinicaltrials.gov/ct2/show/NCT02092896; NLM identifier: NCT02092896. Accessed March 15, 2016.
38. Yale University. A phase 2 trial to examine the effect of subcutaneous exenatide (Bydureon) on glucose control in patients with type 1 diabetes. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; 2000. Available from https://clinicaltrials.gov/ct2/show/NCT01928329; NLM identifier: NCT01928329. Accessed March 15, 2016.
39. GlaxoSmithKline. Albiglutide versus placebo in insulin-treated subjects with new-onset type 1 diabetes mellitus. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; 2000. Available from https://clinicaltrials.gov/ct2/show/NCT02284009; NLM identifier: NCT02284009. Accessed March 15, 2016.
40. Hvidovre University Hospital. The lira pump trial. The effects of liraglutide in patients with insulin pump treated type 1 diabetes: a randomized placebo-controlled trial. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; 2000. Available from https://clinicaltrials.gov/ct2/show/NCT02351232; NLM identifier: NCT02351232. Accessed March 15, 2016.
41. Per-Ola Carlsson. A randomized, double-blinded, placebo-controlled, paralleled designed, investigator sponsored study of the effect of the GLP-1 receptor agonist liraglutide on beta-cell function in C-peptide positive type 1 diabetic patients. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; 2000. Available from https://clinicaltrials.gov/ct2/show/NCT02617654; NLM identifier: NCT02617654. Accessed March 15, 2016.
42. Novo Nordisk. Novo Nordisk completes second and final phase 3a trial with liraglutide as adjunct therapy to insulin for people with type 1 diabetes (NN9211) [Press release], 2015. Available from http://www.novonordisk.com/media/novo-nordisk-news.html. Accessed March 15, 2016.